ACTN4 and hepatocellular carcinoma: The CCK8 assay revealed that the impact of CCT3 knockdown on Sorafenib sensitivity in HCC cells was no longer observed upon simultaneous knockdown of ACTN4 or TFRC (Figs. 5H, S5J).